Q1 2018 Earnings Forecast for CVS Health Corp Issued By SunTrust Banks (CVS)

CVS Health Corp (NYSE:CVS) – Stock analysts at SunTrust Banks increased their Q1 2018 earnings per share estimates for shares of CVS Health in a research note issued on Thursday. SunTrust Banks analyst D. Macdonald now forecasts that the pharmacy operator will earn $1.43 per share for the quarter, up from their previous estimate of $1.40. SunTrust Banks has a “Buy” rating and a $90.00 price target on the stock. SunTrust Banks also issued estimates for CVS Health’s Q3 2018 earnings at $1.32 EPS, Q4 2018 earnings at $1.93 EPS, FY2018 earnings at $6.15 EPS, Q1 2019 earnings at $1.06 EPS, Q2 2019 earnings at $1.26 EPS, Q3 2019 earnings at $1.43 EPS and FY2019 earnings at $5.80 EPS.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.88 by $0.04. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. The firm had revenue of $48.39 billion during the quarter, compared to the consensus estimate of $47.54 billion. During the same quarter in the prior year, the firm earned $1.71 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis.

CVS has been the subject of several other research reports. Loop Capital dropped their price objective on shares of CVS Health from $83.00 to $73.00 and set a “hold” rating for the company in a research note on Tuesday, November 7th. Morgan Stanley raised shares of CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 price objective for the company in a research note on Friday, January 5th. Needham & Company LLC upped their price objective on shares of CVS Health from $85.00 to $88.00 and gave the company a “buy” rating in a research note on Tuesday, January 2nd. Leerink Swann set a $85.00 price objective on shares of CVS Health and gave the company a “buy” rating in a research note on Friday. Finally, Mizuho set a $95.00 price objective on shares of CVS Health and gave the company a “buy” rating in a research note on Wednesday, January 24th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. CVS Health currently has an average rating of “Buy” and a consensus price target of $87.77.

Shares of CVS Health (NYSE:CVS) opened at $69.39 on Monday. CVS Health has a one year low of $66.45 and a one year high of $84.00. The stock has a market cap of $70,290.00, a PE ratio of 11.76, a P/E/G ratio of 1.16 and a beta of 0.92. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.55 and a current ratio of 1.02.

Hedge funds have recently modified their holdings of the company. Fieldpoint Private Securities LLC lifted its holdings in shares of CVS Health by 333.3% in the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after acquiring an additional 1,000 shares during the last quarter. Wealthcare Advisory Partners LLC lifted its holdings in shares of CVS Health by 330.3% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after acquiring an additional 991 shares during the last quarter. Arcadia Investment Management Corp MI lifted its holdings in shares of CVS Health by 119.6% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after acquiring an additional 726 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new position in shares of CVS Health in the 2nd quarter worth approximately $119,000. Finally, Cerebellum GP LLC acquired a new position in shares of CVS Health in the 4th quarter worth approximately $130,000. Hedge funds and other institutional investors own 81.69% of the company’s stock.

In other news, EVP Lisa Bisaccia sold 29,445 shares of the stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total value of $2,208,375.00. Following the completion of the sale, the executive vice president now owns 15,556 shares of the company’s stock, valued at approximately $1,166,700. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.61% of the company’s stock.

The company also recently declared a quarterly dividend, which was paid on Friday, February 2nd. Stockholders of record on Wednesday, January 24th were paid a $0.50 dividend. The ex-dividend date of this dividend was Tuesday, January 23rd. This represents a $2.00 annualized dividend and a dividend yield of 2.88%. CVS Health’s dividend payout ratio (DPR) is 33.90%.

WARNING: “Q1 2018 Earnings Forecast for CVS Health Corp Issued By SunTrust Banks (CVS)” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/02/12/q1-2018-earnings-forecast-for-cvs-health-corp-issued-by-suntrust-banks-cvs.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Earnings History and Estimates for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply